Results 41 to 50 of about 734,316 (316)

Tumor microenvironmental cytokines bound to cancer exosomes determine uptake by cytokine receptor-expressing cells and biodistribution

open access: yesNature Communications, 2021
Cancer derived exosomes are reported to promote metastatic dissemination. Here the authors show that cytokines in the tumor microenvironment bind to exosomes via glycosaminoglycan side chains of proteoglycans, and these exosomes are preferentially taken ...
Luize G. Lima   +11 more
doaj   +1 more source

Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination

open access: yes, 2021
The Tie2 receptor tyrosine kinase is expressed in vascular endothelial cells, tumor-associated macrophages, and tumor cells and has been a major focus of research in therapies targeting the tumor microenvironment.
George S. Karagiannis   +5 more
core   +1 more source

Functional characterization of ABCA4 genetic variants related to Stargardt disease

open access: yesScientific Reports, 2022
The ATP-binding cassette subfamily 4 (ABCA4), a transporter, is localized within the photoreceptors of the retina, and its genetic variants cause retinal dystrophy. Despite the clinical importance of the ABCA4 transporter, a few studies have investigated
Bo Min Kim   +6 more
doaj   +1 more source

DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment

open access: yes, 2021
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by genomic instability. MM cells present various forms of genetic instability, including chromosomal instability, microsatellite instability, and base-pair alterations, as well as
Takayuki Saitoh, Tsukasa Oda
core   +1 more source

Anti-S100A4 Antibody Suppresses Metastasis Formation by Blocking Stroma Cell Invasion

open access: yesNeoplasia: An International Journal for Oncology Research, 2012
The small Ca-binding protein, S100A4, has a well-established metastasis-promoting activity. Moreover, its expression is tightly correlated with poor prognosis in patients with numerous types of cancer.
Jörg Klingelhöfer   +6 more
doaj   +1 more source

Targeting cellular senescence to combat cancer and ageing

open access: yesMolecular Oncology, 2022
Senescence is a complex cellular process that is implicated in various physiological and pathological processes. It is characterized by a stable state of cell growth arrest and by a secretome of diverse pro‐inflammatory factors, chemokines and growth ...
Chen Wang, Xue Hao, Rugang Zhang
doaj   +1 more source

GM‐CSF enhances tumor invasion by elevated MMP‐2, ‐9, and ‐26 expression

open access: yesCancer Medicine, 2013
Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) promotes tumor progression in different tumor models in an autocrine and paracrine manner. However, at the same time GM‐CSF is used in cancer therapies to ameliorate neutropenia.
Claudia M. Gutschalk   +5 more
doaj   +1 more source

Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression

open access: yesCell Death and Disease, 2022
Androgen receptor (AR) signaling plays important roles in breast cancer progression. We show here that Kindlin-2, a focal adhesion protein, is critically involved in the promotion of AR signaling and breast cancer progression.
Luyao Ma   +13 more
doaj   +1 more source

Screening of Molecular Markers of Cisplatin Resistance in Lung Adenocarcinoma and Functional Verification Based on TCGA Database

open access: yesZhongliu Fangzhi Yanjiu, 2022
Objective To explore the related genes that play a key regulatory role in cisplatin resistance in lung adenocarcinoma. Methods Bioinformatics methods were used to download the differentially-expressed genes between cisplatin sensitive group and drug ...
WANG Lin   +5 more
doaj   +1 more source

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

open access: yes, 2023
Cancer immunotherapy has brought significant clinical benefits to numerous patients with malignant disease. However, only a fraction of patients experiences complete and durable responses to currently available immunotherapies.
Dietmar Herndler-Brandstetter   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy